These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 625067)

  • 1. Effect of low phenylalanine diet on murine leukemia L1210.
    Pine MJ
    J Natl Cancer Inst; 1978 Mar; 60(3):633-41. PubMed ID: 625067
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A; Canti G; Goldin A
    Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved host defense against L1210 leukemia by deprivation of dietary phenylalanine.
    Pine MJ
    Nutr Cancer; 1981; 3(2):94-102. PubMed ID: 7346795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1210 leukemia regression in non-immunosuppressed mice with therapeutic transfer of immune spleen cells--therapeutic adoptive transfer against L1210 leukemia.
    Kawashima K; Nagura E; Nagase F; Kumazawa T; Nakashima I; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1987 Sep; 50(6):1174-82. PubMed ID: 3687342
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM; Kawashima K; Nakashima I; Nagase F
    Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
    Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
    Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
    Kataoka T; Kobayashi H; Sakurai Y
    Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor.
    Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
    Cancer Res; 1977 Dec; 37(12):4416-9. PubMed ID: 922733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade tumor-specific immunity induced by L1210 leukemia variants obtained from the culture of L1210 cells fused with Lesch-Nyhan fibroblasts.
    Kawashima K; Nagura E; Watanabe E; Mizoguchi K; Saga S; Isobe K; Nakashima I; Yamada K; Oikawa T; Kojima K
    Int J Cancer; 1983 Oct; 32(4):507-14. PubMed ID: 6618710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.
    Mihich E
    Cancer Res; 1969 Apr; 29(4):848-54. PubMed ID: 4887203
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells.
    Ohno R; Kodera Y; Ogura M; Yamada H
    Gan; 1984 Feb; 75(2):187-92. PubMed ID: 6428959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
    Nicolin A; Bini A; Franco P; Goldin A
    Cancer Chemother Rep; 1974; 58(3):325-30. PubMed ID: 4841716
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of cyclosporin A mediated immunity in L1210 leukaemia.
    Slater LM; Wetzel M; Cho J; Sweet P
    Br J Cancer; 1991 Dec; 64(6):1098-102. PubMed ID: 1764373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of tumor resistance in mice by L1210 leukemia cells persistently infected with HVJ (Sendai virus).
    Takeyama H; Kawashima K; Yamada K; Ito Y
    Gan; 1979 Aug; 70(4):493-501. PubMed ID: 229053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory factors specifically associated with a spontaneously regressing tumor subline of the murine leukemia L1210.
    Koo PH
    J Immunol; 1981 Jul; 127(1):373-9. PubMed ID: 7016996
    [No Abstract]   [Full Text] [Related]  

  • 18. Thymocyte and splenocyte subpopulations in normal and leukemia-bearing mice after adrenalectomy.
    Kawiak J; Hoser G; Malendowicz LK; Miks B; Skurzak H
    Folia Histochem Cytobiol; 1996; 34(2):75-8. PubMed ID: 8875214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressor T cells induced by soluble immune complexes can adoptively transfer inhibition of cytophilic antibody receptors on macrophages.
    Rao VS; Bennett JA; Grodzicki RL; Mitchell MS
    Cell Immunol; 1979 Sep; 46(2):227-38. PubMed ID: 314850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.